Andrx First Horizon Collaboration

From the Release of March 2, 2005:

Andrx Corporation today announced that it has entered into agreements with First Horizon Pharmaceutical Corporation for the sale and licensing of certain rights to its Fortamet and Altoprev brand pharmaceutical products. First Horizon has agreed to pay Andrx $50 million at closing and up to $35 million when Andrx achieves and maintains certain defined manufacturing service levels. Andrx is also entitled to royalties on net sales of both products, as defined. Andrx and First Horizon have also entered into a long-term manufacturing and supply arrangement."

The Agreement to License and Purchase is here, and the Manufacturing and Supply Agreement is here.